The transcription factor Bcl-6 orchestrates germinal center (GC) reactions through its actions in B cells and T cells and regulates inflammatory signaling in macrophages. Here we found that genetic replacement with mutated Bcl6 encoding Bcl-6 that cannot bind corepressors to its BTB domain resulted in disruption of the formation of GCs and affinity maturation of immunoglobulins due to a defect in the proliferation and survival of B cells. In contrast, loss of function of the BTB domain had no effect on the differentiation and function of follicular helper T cells or that of other helper T cell subsets. Bcl6-null mice had a lethal inflammatory phenotype, whereas mice with a mutant BTB domain had normal healthy lives with no inflammation. The repression of inflammatory responses by Bcl-6 in macrophages was accordingly independent of the repressor function of the BTB domain. Bcl-6 thus mediates its actions through lineage-specific biochemical functions. npg
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Bcl-6 is a transcriptional repressor originally identified as being encoded by a locus frequently translocated in diffuse large B cell lymphomas (DLBCLs) 1 . During normal development, Bcl-6 has critical functions in various cell types of the adaptive and innate compartments of the immune system. Bcl-6 expression undergoes substantial upregulation in B cells after challenge with T cell-dependent antigens 2 , and Bcl-6 is required for the formation of germinal centers (GCs) in which B cells undergo affinity maturation of immunoglobulins. Bcl-6-deficient (Bcl6 -/-) mice do not form GCs and thus are unable to generate high-affinity antibodies [3] [4] [5] . The proposed biological function of Bcl-6 in B cells in the GC is to facilitate the simultaneous rapid proliferation and tolerance to the genomic damage that occurs during clonal expansion and somatic hypermutation by directly repressing genes encoding molecules involved in DNA-damage sensing and checkpoints, such as ATR 6 , CHEK1 (ref. 7) , EP300 (ref. 8) , TP53 (ref. 9) and CDKN1A 10 . Follicular helper T cells (T FH cells), specifically those in GCs, are specialized CD4 + helper T cells that provide help to B cells during the GC reaction 11, 12 . Bcl-6 expression is upregulated during the differentiation of T FH cells, and Bcl6 -/-T cells do not differentiate into T FH cells in vivo [13] [14] [15] . Constitutive expression of Bcl-6 enhances the differentiation of T FH cells [14] [15] [16] . The requirement for Bcl-6 in both B cells and T FH cells in GCs is cell autonomous, and loss of Bcl-6 in either cell type leads to abrogation of the GC reaction 17 . Bcl-6 also has an important role in macrophages, in which it mediates a dampening effect on inflammatory signaling through repression of chemokine expression and target genes of the transcription factor NF-κB 18, 19 . Bcl6 -/-mice develop a lethal inflammatory disease caused by the interaction and crosstalk between macrophages and helper T cells.
Bcl-6 is a member of the BTB-zinc finger family of proteins. Its BTB domain forms an obligate homodimer and it contains C2H2 zinc fingers that bind to DNA. The interface between monomers of the Bcl-6 BTB domain creates two symmetrical extended lateral grooves that form docking sites for the corepressors SMRT, NCOR and BCOR [20] [21] [22] . Those three corepressors bind to Bcl-6 via an unstructured 18-amino acid Bcl-6-binding domain 23 . The Bcl-6-binding domains of NCOR and SMRT are identical, whereas that of BCOR is completely different, yet all three bind to the lateral groove of the Bcl-6 BTB domain in perfectly overlapping configurations 23, 24 . Substitution of lysine for asparagine at position 21 (N21K) and of alanine for histamine at position 116 (H116A) in the Bcl-6 BTB domain completely abrogates the binding of Bcl-6 to NCOR, SMRT and BCOR without impairing folding or dimerization 23 . Mutant Bcl-6 with those N21K and H116A substitutions in its BTB domain is completely inactive, which indicates that the lateral groove-Bcl-6-binding domain interface is responsible for the repressor activity of the Bcl-6 BTB domain 23 . However, Bcl-6 also has a middle autonomous repression region often called 'repression domain 2' (RD2) 25 , which may recruit other corepressors, such as NuRD and CTBP 26, 27 . The sequence of the reported Bcl-6 consensus binding site (TTCCT(A/C)GAA, where A/C indicates either adenosine or cytosine) overlaps that of STAT transcription factor-binding sites 25, 28, 29 , and several lines of evidence indicate that Bcl-6 may antagonize STAT signaling, with potential relevance for inflammatory and innate immunological functions 3, 30, 31 .
Collectively, the data suggest complex biological roles for Bcl-6 in the immune system. However, the link between the transcriptional mechanisms of action of Bcl-6 and its biological actions in the immune system remains unknown. Here we generated a knock-in mouse model Impaired GC formation in Bcl6 BTBMUT mice Phenotypic analysis showed normal early development of B cells in the bone marrow and spleens of Bcl6 BTBMUT mice, as well as normal distribution of peripheral T cells ( Supplementary Fig. 3a-c) . Bcl6 BTBMUT mice also formed normal splenic primary lymphoid follicles (data not shown). Analysis of the spontaneous formation of GCs in spleens of unimmunized mice by staining with peanut agglutinin showed a few small GCs scattered in Bcl6 +/+ mice, whereas none were present in Bcl6 BTBMUT mice (data not shown). After immunization with sheep red blood cells (SRBCs), a T cell-dependent antigen, Bcl6 BTBMUT mice developed only a few, scattered and small peanut agglutinin-positive and Bcl-6 + cell clusters (Fig. 1a) . Serial examination of GCs by immunohistochemistry at days 7, 10 and 14 after immunization with SRBCs showed that Bcl6 BTBMUT mice had considerably smaller and fewer GCs than Bcl6 +/+ mice had at all three time points (Fig. 1b,c) . Lymph nodes in Peyer's patches of in Bcl6 BTBMUT mice showed a similar loss of GCs and the presence of residual cell clusters ( Supplementary  Fig. 4a) , which emphasized the general requirement for Bcl-6 BTB domain-mediated repression in the formation of GCs.
To better understand the mechanism of the GC impairment in Bcl6 BTBMUT mice, we first compared the frequency of GC B cells (CD38 lo-neg Fas + B220 + ) among splenic B cells from Bcl6 +/+ , Bcl6 -/-and Bcl6 BTBMUT in which the endogenous Bcl6 locus encodes a mutant form of Bcl-6 protein with the N21K and H116A point substitutions in the BTB domain (Bcl6 BTBMUT ). The facts that SMRT, NCOR and BCOR are coexpressed with Bcl-6 in the relevant cell types and that the mechanism of the BTB domain is the only well-characterized biochemical function of Bcl-6 favor the proposal that the biological 'readout' of such a knock-in model would be most rigorously interpretable. Notably, our data suggest that the transcriptional mechanisms of action of Bcl-6 are specific to the lineage and biological function, with notable implications for the general understanding of how Bcl-6 and other transcription factors work, as well as for the 'translation' of such results into the clinical use of inhibitors of Bcl-6.
RESULTS

Viability of Bcl6 BTBMUT mice
To address the biological function of interactions between the Bcl-6 BTB domain and its corepressors in vivo, we introduced point mutations in exon 3 and exon 4 of Bcl6 that resulted in the desired N21K and H116A substitutions in the BTB domain (Bcl6 BTBMUT ; Supplementary Fig. 1a,b) . We crossed Bcl6 +/BTBMUT mice heterozygous for the neomycin-resistance cassette with mice with transgenic expression of Cre recombinase from the adenovirus EIIa promoter (which targets Cre expression to the early mouse embryo) to generate heterozygous Bcl6 +/BTBMUT mice, which we then intercrossed to generate homozygous Bcl6 BTBMUT/BTBMUT mice (called 'Bcl6 BTBMUT mice' here; Supplementary Fig. 2a ). Bcl6 BTBMUT mice were born at the expected Mendelian ratios, were viable and were developmentally indistinguishable from their Bcl6 +/+ littermates (data not shown), in contrast to Bcl6 -/-mice, which are runted and sickly and are born at lower than the expected ratios. Quantitative RT-PCR and immunoblot analysis showed normal expression of mutated Bcl6 transcripts and mutant Bcl-6 protein in splenic B220 + cells from Bcl6 BTBMUT mice (Supplementary Fig. 2b ). Sequencing of genomic DNA from tails of Bcl6 BTBMUT mice confirmed the presence of the introduced point mutations (Supplementary Fig. 2c ). Quantitative npg A r t i c l e s NP 26 -BSA (NP conjugated to bovine serum albumin (BSA) at a molecular ratio of 26:1; Fig. 2a ). In contrast, at day 21 after immunization with NP-CGG, the titers of NP-specific immunoglobulin G1 (IgG1) and IgG2a were significantly lower in Bcl6 BTBMUT mice than in Bcl6 +/+ mice, with a trend toward lower titers of other immunoglobulins (Fig. 2a) . Early after immunization (at day 7 d), Bcl6 BTBMUT and Bcl6 +/+ mice formed a similar number of antigen-specific IgM-or IgG-secreting cells (Fig. 2b ) and plasma cells (NP + CD138 + CD11c -CD4 -CD8 -B220 neg-lo cells; Fig. 2c ). However, at that time point, the abundance of antigen-specific GC B cells (NP + GL7 + B220 + ) in Bcl6 BTBMUT mice was less than 20% of that in immunized Bcl6 +/+ mice (Fig. 2c) . Immunized Bcl6 BTBMUT mice also had much lower titers of high-affinity IgG1 and IgG2a able to bind NP 4 -BSA (NP conjugated to BSA at z molecular ratio of 4:1), which recognizes high-affinity immunoglobulin, than did their Bcl6 +/+ counterparts ( Fig. 2d) , indicative of impaired affinity maturation. That defect was also evident by calculation of the ratio of IgG1 or IgG2a titers detected with NP 4 -BSA to those detected with NP 26 -BSA (Fig. 2e) . Therefore, recruitment of corepressors by the BTB domain was indispensable for Bcl-6 to drive the T cell-dependent formation of highaffinity immunoglobulins.
B cell-intrinsic GC impairment in Bcl6 BTBMUT mice Bcl6 -/-mice have cell-autonomous defects in both GC B cells and GC T FH cells 4, 5, [13] [14] [15] . To determine whether Bcl6 BTBMUT mice had similar defects, we generated mixed-bone marrow chimeras by transplanting a mixture of congenic CD45.1 + Bcl6 +/+ bone marrow cells (50%) together with CD45.2 + bone marrow cells from Bcl6 +/+ , Bcl6 -/-or Bcl6 BTBMUT mice (50%) into sublethally irradiated mice deficient in recombination-activating gene 1 (Rag1 -/-mice), which have a congenital deficiency in mature B cells and T cells (Fig. 3a) . All CD45.2 + donor cells showed a normal developmental pattern for cells of the T or B lineage before the GC stage (date not shown). As expected, was 0.38% ± 0.14%, and this increased to 5.07% ± 0.85% at day 10 after immunization ( Fig. 1d) . As reported before [3] [4] [5] , GC B cells were essentially undetectable in Bcl6 -/-mice before and after immunization (<0.2%). Likewise, Bcl6 BTBMUT mice had an almost complete loss of GC B cells, with a frequency of 0.23% ± 0.09% before immunization and 0.57% ± 0.068% at day 10 after immunization ( Fig. 1d) .
We next examined the development of T FH cells (CXCR5 lo-hi PD-1 lo-hi ) and T FH cells in the GC (CXCR5 hi PD-1 hi ). The frequency of GC T FH cells among splenic CD4 + cells was much lower in immunized Bcl6 BTBMUT mice (2% ± 0.3%) than in Bcl6 +/+ mice (8.05% ± 1.9%; Fig. 1e ). The proportion of CXCR5 lo PD-1 lo T FH cells, a population that includes pre-GC T FH cells, was also lower in Bcl6 BTBMUT mice than in Bcl6 +/+ mice (Fig. 1e) . Accordingly, Bcl6 BTBMUT mice had significantly fewer total T FH cells, which included GC T FH cells and CXCR5 lo PD-1 lo T FH cells, than did Bcl6 +/+ mice (Fig. 1e) . We observed similar defects in Bcl6 BTBMUT mice challenged with a second T cell-dependent antigen, NP-CGG (4-hydroxy-3-nitrophenylacetyl conjugated to chicken γ-globulin; Supplementary Fig. 4b ). Collectively, these results demonstrated that BTB domain-mediated transcriptional repression was absolutely required for the formation of GCs.
Impaired immunoglobulin affinity maturation in Bcl6 BTBMUT mice Bcl-6 is not required for the response to T cell-independent antigens, and accordingly, Bcl6 BTBMUT mice had normal low-affinity antibody responses to the T cell-independent antigen of NP conjugated to the hydrophilic polysaccharide Ficoll (data not shown). The T cell-dependent B cell immune response triggers both an extrafollicular response, which generates short-lived plasma cells and an early wave of low-affinity antibody production, and a GC response, which gives rise to long-lived plasma or memory cells and a later wave of high-affinity antibodies. Immunization with NP-CGG induced a normal extrafollicular response in Bcl6 BTBMUT mice, with the expected production of low-affinity immunoglobulin specific to Fig. 3b,c) . In contrast, whereas CD45.2 + donor Bcl6 BTBMUT cells showed profound deficiency in formation of GC B cells, they formed normal numbers of T FH cells (Fig. 3b,c) . The lower abundance of T FH cells noted in the Bcl6 BTBMUT setting was thus secondary to the lack of GC B cells. To determine whether impaired affinity maturation of immunoglobulins in Bcl6 BTBMUT mice was also intrinsic to B cells, we constructed chimeras by transferring bone marrow from µMT mice (which lack B cells; 50%) along with bone marrow from Bcl6 +/+ , Bcl6 BTBMUT or Bcl6 -/-mice (50%) into sublethally irradiated Rag1 -/-mice (Supplementary Fig. 5a ). The µMT bone marrow provides a source of normal T cells but no B cells; thus, all B cells in these chimeras originate from Bcl6 +/+ , Bcl6 BTBMUT or Bcl6 -/-donor bone marrow cells. Chimeras given a mixture containing Bcl6 BTBMUT bone marrow formed few GC B cells and GCs after SRBC immunization, similar to chimeras given a mixture containing Bcl6 -/-bone marrow ( Supplementary Fig. 5b-d) . The titers of NP-specific IgG1 antibodies in chimeras given a mixture containing Bcl6 BTBMUT bone marrow were 16% or 6% of those in chimeras given a mixture containing Bcl6 +/+ bone marrow after immunization with NP-CGG when NP 26 -BSA or NP 4 -BSA was used as capture antigen, respectively (Fig. 3d) . The ratio of titers detected with NP 4 -BSA to those detected with NP 26 -BSA was significantly lower in chimeras given a mixture containing Bcl6 BTBMUT bone marrow than in those given a mixture containing Bcl6 +/+ bone marrow (Fig. 3e) . These results demonstrated a B cell-intrinsic requirement for BTB domain-mediated repression in the affinity maturation of immunoglobulins and the development of functional GC B cells.
Lower proliferation and survival of Bcl6 BTBMUT GC B cells Bcl-6 suppresses checkpoints that control cellular proliferation and survival, which may explain how GC B cells proliferate so rapidly and tolerate somatic hypermutation 6, 7, 9, 10 . We reasoned that the inability to achieve that proliferative and prosurvival phenotype might explain the failure of Bcl6 BTBMUT mice to form functional GCs. We determined the rate of cell proliferation in vivo by measuring incorporation of the thymidine analog BrdU. Less than 1% of non-GC B cells incorporated BrdU in either Bcl6 +/+ mice or Bcl6 BTBMUT mice (Supplementary Fig. 6a) . Notably, whereas 32% ± 4.3% of GC B cells in Bcl6 +/+ mice incorporated BrdU, only 16.8% ± 3.1% of GC B cells in Bcl6 BTBMUT mice were BrdU + (Fig. 4a) . Cell-cycle analysis showed a greater fraction of GC B cells arrested in the G1 phase with correspondingly fewer in S phase in Bcl6 BTBMUT mice than in Bcl6 +/+ mice (Fig. 4a) . We next assessed the abundance of apoptotic cells by evaluating active caspase and staining with the membrane-impermeable DNA-intercalating dye 7-AAD. Whereas 14.7% ± 1.1% of GC B cells in Bcl6 +/+ mice were positive for activation of total caspase, this fraction was higher (21% ± 1.75%) in Bcl6 BTBMUT mice (Fig. 4b) . Bcl6 BTBMUT GC B cells also had more caspase-3 activity than did Bcl6 +/+ GC B cells (7-AAD -cells, 6% ± 1.1% (mutant) versus 3% ± 0.8% (wild-type); 7-AAD + cells, 10% ± 0.6% (mutant) versus 5% ± 1.2% (wild-type); Fig. 4b) . Notably, after 3 h of incubation, Bcl6 BTBMUT GC B cells still included a greater proportion of positive for active caspase-3 than did Bcl6 +/+ GC B cells (7-AAD -cells, 10% ± 1.5% (mutant) versus 6.7 ± 2.3% Fig. 6b ). These data indicated that the lateral groove of the Bcl-6 BTB domain was needed to facilitate the rapid proliferation and survival of GC B cells. Along those lines, we assessed the binding profiles of Bcl-6, BCOR and SMRT in primary human GC B cells by ChIP followed by deep sequencing (ChIP-seq) and found that both corepressors were present together with Bcl-6 at the promoters of key checkpoint target genes, including CDKN1A, TP53 and ATR (Fig. 4c) . The presence of such complexes was consistent with published data showing that expression of those genes is induced by exposure to peptides that block the lateral groove of the BTB domain 6, 28, 32 .
Bcl6 BTBMUT T FH cells support normal GC responses
The results presented above indicated that the Bcl-6 BTB domain was dispensable for the formation of T FH cells (Fig. 3c) . To determine whether Bcl6 BTBMUT T FH cells were able to support GC functions, including the affinity maturation of immunoglobulins, we generated chimeras by transferring bone marrow from Tcrb -/-Tcrd -/-mice (which lack the genes encoding the T cell antigen receptor β-and δ-chains; 80%) along with bone marrow from Bcl6 +/+ , Bcl6 BTBMUT or Bcl6 -/-mice (20%) into sublethally irradiated Rag1 -/-mice ( Supplementary  Fig. 7a ). Tcrb -/-Tcrd -/-bone marrow cells provide a source of normal B cells but no T cells; thus, the chimeras would be able to form functional GCs only if the other donor bone marrow provided a source of normal T FH cells. After immunization with SRBCs, chimeras that received a mixture containing Bcl6 BTBMUT bone marrow formed an abundance of GC B cells and normal GCs in spleens equal to that formed by chimeras that received a mixture containing Bcl6 +/+ bone marrow, but those that received a mixture containing Bcl6 -/-bone marrow did not (Fig. 5a,b and Supplementary Fig. 7b) . Moreover, titers of NP-specific IgG1 antibodies in NP-CGG-immunized chimeras that received a mixture containing Bcl6 BTBMUT bone marrow were indistinguishable from those in chimeras that received a mixture containing Bcl6 +/+ bone marrow when either NP 26 -BSA or NP 4 -BSA was used as the capture antigen (Fig. 5c) . Their ratio of titers detected with NP 4 -BSA to those detected with NP 26 -BSA was also similar to that in chimeras that received a mixture containing Bcl6 +/+ bone marrow (Fig. 5d) . Thus, Bcl6 BTBMUT mice formed fully functionally competent T FH cells. Fig. 6a,b) . In contrast, Bcl6 BTBMUT mice had an abundance of T H 2 and T H 17 cells similar to that of Bcl6 +/+ mice (0.98 ± 0.3% (Bcl6 BTBMUT ) versus 1 ± 0.2% (Bcl6 +/+ ); 0.62 ± 0.3% (Bcl6 BTBMUT ) versus 0.6 ± 0.2% (Bcl6 +/+ ); Fig. 6a,b) . Thus, the lateral groove of the BTB domain was not involved in Bcl-6-mediated suppression of T H 2 or T H 17 differentiation in vivo.
Normal differentiation of helper T cell subsets in
No Bcl6 -/-inflammatory phenotype in Bcl6 BTBMUT mice Bcl6 -/-mice are born at lower than expected frequencies, are runted and develop a severe T H 2-type inflammatory syndrome that involves many organs and frequently includes the lungs and spleen 3, 4 . However, we observed that Bcl6 BTBMUT mice were born at the expected 
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Mendelian frequencies, were developmentally indistinguishable from their Bcl6 +/+ littermates and had normal body weights (Fig. 7a) . By 6 weeks of age, more than half of the Bcl6 -/-mice had died, whereas all Bcl6 BTBMUT mice remained healthy even after 1 year of monitoring. Bcl6 -/-mice had the expected infiltrates of inflammatory cells in their lungs, as well as multinodular lesions characterized by the infiltration of eosinophils into the spleen, whereas histological studies of Bcl6 BTBMUT organs (including lungs, spleen, heart, liver, thymus, kidney and intestine) showed no such infiltrates ( Fig. 7b and Supplementary Fig. 8a ). We confirmed that the mice had that phenotype in two independent founder lines with different genetic backgrounds (data not shown).
Minimal effect on chemokines in Bcl6 BTBMUT macrophages Bcl6 -/-macrophages have substantial upregulation of the expression of inflammatory chemokines such as CCL2, CCL3, CCL6, CCL7 and IL-1a, which are believed to be critical mediators of the lethal inflammatory response in Bcl6 -/-mice 18, 19 . Bcl-6 also suppresses macrophage proliferation through repression of CCND2, a critical driver of the cell cycle 35 . The unexpected lack of an inflammatory phenotype in Bcl6 BTBMUT mice prompted us to measure chemokine expression and the proliferation of macrophages isolated from these mice. We first measured the abundance of mRNA from genes encoding molecules involved in the inflammatory response (Ccl2, Ccl3, Ccl6, Il1a, Ccl7 and Ccnd2) in resting and lipopolysaccharide (LPS)-stimulated macrophages from Bcl6 +/+ , Bcl6 BTBMUT and Bcl6 -/-mice, by quantitative PCR. Most of these genes had 20-fold higher expression in resting Bcl6 -/-macrophages than in resting Bcl6 +/+ cells and were further induced by treatment with LPS (Fig. 7c) . In contrast, Bcl6 BTBMUT macrophages showed no more than 1.4-to 4-fold higher basal expression of these genes relative to their expression in Bcl6 +/+ cells, and that limited higher expression was not further enhanced by LPS treatment (Fig. 7c) . As expected, Bcl6 -/-macrophages divided faster than Bcl6 +/+ macrophages did, whereas Bcl6 BTBMUT macrophages had a proliferation rate very similar to that of Bcl6 +/+ macrophages (Fig. 7d) .
To determine whether other Bcl-6 domains contribute to the repression of genes encoding inflammatory molecules to a greater extent than the BTB domain does, we transduced Bcl6 -/-macrophages with retrovirus expressing wild-type Bcl6 or Bcl6 with various mutations. Bcl6 -/-macrophages transduced to express wild-type Bcl6, Bcl6 with point mutations that result in the substitutions BN21K and H116A (as in Bcl6 BTBMUT mice), Bcl6 with mutations that result in inactivation of the RD2 repression domain 36 or Bcl6 with both sets of mutations retained the ability to suppress the expression 
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A r t i c l e s of genes encoding chemokines and inflammatory molecules (Fig. 7e) .
In contrast, those transduced to express Bcl6 with a mutation that affects the third C2H2 zinc finger of Bcl-6 that abolishes DNA binding without affecting localization to the nucleus 37 were completely unable to repress those target genes (Fig. 7e) . Hence, whereas DNA binding was required for the repression of chemokine expression, the lateral groove of the BTB domain was dispensable for that function, consistent with the lack of inflammatory phenotype of Bcl6 BTBMUT mice. ChIP-seq analysis of Bcl-6 in macrophages has shown that Bcl-6-binding sites show considerable enrichment for STAT-binding motifs, including those in the chemokine-encoding genes we assessed here 19 . Bcl-6 has been proposed to potentially compete with STAT proteins for binding to certain target genes 30, 31, 38 . Loss of the binding of Bcl-6 to DNA might thus enhance the recruitment of STAT proteins to those inflammation-related loci. Here we assessed STAT5 as an example. Bcl6 +/+ and Bcl6 -/-primary mouse macrophages have a similar abundance of active STAT5 (ref. 35) . By quantitative ChIP assay, we observed reciprocal changes in the binding of STAT5 and Bcl-6 at the promoters of Ccl2 and Ccnd2 in Bcl6 +/+ versus Bcl6 -/-primary mouse macrophages, with substantially enhanced enrichment for STAT5 in the absence of Bcl-6 ( Supplementary Fig. 8b,c) . More notably, expression of wild-type Bcl6 plus Bcl6 with the mutations resulting in the BN21K and H116A substitutions and inactivation of the RD2 repression domain (as described above) in Bcl6 -/-primary mouse macrophages impaired enrichment for STAT5 at both of those chemokine-encoding loci, but expression of wild-type Bcl6 plus Bcl6 with the mutation affecting its third C2H2 zinc finger (described above) did not (Fig. 7f) .
DISCUSSION
Given that Bcl-6 and corepressors of its BTB domain are expressed together in most Bcl-6-expressing tissues, the biochemical function of Bcl-6 would be expected to be similar among cell types, and its tissuespecific function would be expected to be perhaps mediated by binding to distinct sets of target genes. Indeed, genome-localization studies of Bcl-6 in various cell types have suggested that its transcriptional targets are partially cell type specific 19, 28, 29 . However, evidence of a more profound, biochemical level of functional diversification has been hinted at by studies of cell-penetrating peptides designed to dissociate the BTB domain of Bcl-6 from its corepressors 39, 40 . The administration of such peptides to mice bearing human lymphoma xenografts induces growth arrest and apoptosis in lymphoma cells but does not induce the Bcl6 -/-inflammatory phenotype 39, 40 . Unfortunately, the interpretation of such peptide studies has been limited by the unknown kinetics and degree of inhibition of Bcl-6 in various cell types, as well as a relatively time-limited exposure. Our introduction of point mutations in the native Bcl6 locus in mice afforded constitutive loss of the repressor function of the BTB domain in all tissues while preserving proper timing and amount of expression, which allowed us to gain critical insights into the function of this unique biochemical mechanism of Bcl-6.
Bcl6 BTBMUT mice had a normal early extrafollicular response but an impaired late GC response after immunization with a T cell-dependent antigen. Notably, loss of the repression function of the BTB domain manifested as failure of GC B cells to proliferate and survive, even in the presence of wild-type T FH cells and a wild-type microenvironment. Hence, the function of the BTB domain of Bcl-6 was specifically 6, 32 . One implication of these results is that the same biochemical function through which Bcl-6 specifically mediates the GC B cell phenotype also drives the survival and proliferation of DLBCL cells. Targeting the BTB domain of Bcl-6 with peptides or small-molecule inhibitors kills DLBCL cell lines in vitro and in vivo, as well as primary human DLBCL cells ex vivo [39] [40] [41] . Thus, DLBCLs are essentially driven by a normal transcriptional mechanism derived from their cell of origin.
Similar to Bcl6 -/-mice, Bcl6 BTBMUT mice had fewer CXCR5 + PD-1 + T FH cells and GC T FH cells. However, in contrast to the T cell development in Bcl6 -/-mice, Bcl6 BTBMUT mice generated perfectly functional T FH cells after immunization in the presence of normal cognate B cells. As cognate B cells are absolutely required for the differentiation and maintenance of GC T FH cells [42] [43] [44] , the defect in GC T FH cells in Bcl6 BTBMUT mice was probably secondary to the defect in the B cell compartment. The finding that the deficit in CXCR5 + PD-1 + T FH cells was less pronounced was probably related to the preservation of the early, extrafollicular phase of the immune response that we observed in Bcl6 BTBMUT mice. The mechanisms underlying the deficiencies in the T FH cell phenotype in Bcl6 BTBMUT and Bcl6 -/-mice are completely different. Further research is thus needed to explain the biochemical mechanism through which Bcl-6 mediates the T FH cell phenotype. Perhaps different sets of corepressors that bind to different sites on Bcl-6 are involved.
Another salient finding of our phenotypic analysis of Bcl6 BTBMUT mice was the absence of the lethal inflammatory disease of Bcl6 -/-mice, which indicated that the lateral groove of the BTB domain was dispensable for the functions of Bcl-6 in the innate immune system. In macrophages, Bcl-6 attenuates inflammatory responses through the repression of chemokines and NF-κB target genes 18, 19, 35 . Enhanced inflammatory signaling in Bcl6 -/-macrophages also deregulates T cell development, which results in skewing toward T H 2 and T H 17 differentiation 33 and eventually forms a vicious circle that leads to destructive infiltration of various tissues by T cells. Loss of Bcl6 is also reported to confer an atherogenic and xanthomatous tendinitis phenotype 45 reminiscent of human familial hypercholesterolemia. We did not observe any of those phenotypes in Bcl6 BTBMUT mice. The expression of inflammatory cytokines was at best partially deregulated and proliferation was normal in Bcl6 BTBMUT macrophages relative to that in Bcl6 -/-macrophages. It was the DNA-binding domain and not the BTB domain of Bcl-6 that was most critical in the repression of chemokine expression in Bcl6 -/-macrophages. The explanation for that finding may be found in how transcriptional repressors and activators can compete for promoter occupancy by mutually exclusive binding to overlapping DNA elements 46 . Indeed Bcl-6 and STAT proteins bind to overlapping consensus binding sites 19, 25, 28, 29 . Our results presented here showed reciprocal binding of Bcl-6 and STAT5 to key macrophage genes encoding inflammatory molecules. This, passive DNA-binding competition between Bcl-6 and STAT proteins, rather than the interaction of Bcl-6 with its corepressors, may be the dominant biochemical function of Bcl-6 in innate immunity.
Finally, our study has implications for the clinical use of inhibitors of Bcl-6 designed to disrupt the binding of corepressors to its BTB domain 39, 40 , which are now being 'translated' for use in the treatment of patients with Bcl-6-dependent tumors. The potential for such drugs to cause systemic inflammation and atherosclerosis is a potential concern for humans treated with such compounds.
Our data have shown that such side effects would be unlikely to occur, consistent with reported toxicity studies of such inhibitors in mice 39 . In summary, by constructing a knock-in mutation that results in constitutive disruption of the binding of corepressors to the BTB domain, we were able to demonstrate that Bcl-6 mediated immunological lineage-specific effects through various protein interactions and thus provide a new paradigm for the functional diversification of transcription factors.
METHODS
Methods and any associated references are available in the online version of the paper.
Accession codes. GEO: microarray data, ChIP-seq data, GSE43350. off the dishes and washed with PBS, then were replated in complete DMEM. Cells were allowed to adhere overnight, and then fresh medium, with or without 5 µg/ml LPS (from Eshecrichia coli strain 055:B5; Sigma-Aldrich), was added for 6 h before collection of cells. Expression constructs for Bcl6 +/+ and Bcl6 with point mutations that result in the substitutions BN21K and H116A have been described 24 . Expression constructs for the latter and for Bcl6 with mutations that result in inactivation of RD2 or Bcl6 with mutation affecting its third C2H2 zinc finger were generated with QuikChange II Site-Directed Mutagenesis kits (Agilent Technologies). The cDNA fragments for Bcl6 +/+ and those mutated forms of Bcl6 were subcloned into MIGR1-GFP or MIGR1-puromycin retroviral expression vector. Viral supernatants were prepared with Plat-E cells according to a standard protocol. For retroviral infection, bone marrow cells were maintained in complete DMEM for 4 d and infected with viral supernatants in the presence of 8 µg/ml polybrene (Sigma). For MIGR1-GFP-infected cells, GFP + cells were sorted 7 d after infection for analysis of gene expression by quantitative RT-PCR. For MIGR1-puromycin-infected cells, puromycin-resistant cells were selected by the addition of 2 µg/ml puromycin (Invitrogen) and used for quantitative ChIP assays.
Immunohistology. Spleens and Peyer's patches of the terminal ileum were fixed in 4% paraformaldehyde and embedded in paraffin. Sections of each sample 6 µm in thickness were prepared, cleared in xylene and hydrated through a descending alcohol series to distilled water. Slides were boiled for 20 mi in citrate antigen retrieval buffer, followed by washes under running water. Endogenous peroxidase activity was blocked by treatment of the sections for 20 min with 3% hydrogen peroxide in methanol. Tissue sections were then incubated overnight at 4 °C with biotin-conjugated peanut agglutinin (Vector Laboratories). After a further wash in TBS, streptavidin-horseradish peroxidase was added, followed by incubation for 30 min. Horseradish peroxidas activity was detected with a DAB kit (Vector Laboratories). Finally, sections were counterstained with hematoxylin if necessary. For double staining, sections were incubated overnight at 4 °C with anti-Bcl-6 (N3; Santa Cruz), followed incubation for 1 h with biotin-conjugated secondary antibody (sc-2030; Santa Cruz). Streptavidin-alkaline phosphatase was added after a further wash in TBS followed by incubation for 30 min. Alkaline phosphatase activity was detected with a Alkaline Phosphatase Substrate Kit III (Vector Laboratories). Sections were boiled for 10 min followed by incubation with biotin-conjugated anti-B220 (RA3-6B2; Caltag Metsystems), then incubation with streptavidin-horseradish peroxidase. Horseradish peroxidase activity was detected with a DAB kit (Vector Laboratories).
Statistical analysis. Student's t-test was used for statistical analysis with the software GraphPad Prism 5. P values above 0.05 were considered not significant.
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